Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 34
0
Funds holding %
of 6,812 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 101
68% more call options, than puts
Call options by funds: $360M | Put options by funds: $215M
50% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 62
33% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 8 (+2) [Q3]
20% more capital invested
Capital invested by funds: $4.43B [Q2] → $5.3B (+$866M) [Q3]
8% more funds holding
Funds holding: 385 [Q2] → 416 (+31) [Q3]
0.62% more ownership
Funds ownership: 75.77% [Q2] → 76.39% (+0.62%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$74
83%
upside
Avg. target
$95
135%
upside
High target
$109
170%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 26% 1-year accuracy 99 / 384 met price target | 152%upside $102 | Buy Reiterated | 20 Dec 2024 |
Piper Sandler Biren Amin 10% 1-year accuracy 2 / 20 met price target | 83%upside $74 | Overweight Initiated | 2 Dec 2024 |
B. Riley Securities Mayank Mamtani 30% 1-year accuracy 7 / 23 met price target | 170%upside $109 | Buy Initiated | 22 Nov 2024 |
Financial journalist opinion
Based on 28 articles about VKTX published over the past 30 days
Neutral
Accesswire
22 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX NEW YORK, December 27, 2024 (PRNEWSWIRE)Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Positive
The Motley Fool
1 day ago
3 Stocks That Could Be Monster Winners in 2025
What do many kids like most about the coming of a new year? The fireworks.
Neutral
PRNewsWire
2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Negative
The Motley Fool
1 week ago
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
The weight-loss biotech Viking Therapeutics (VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (MRK -1.48%).
Positive
The Motley Fool
1 week ago
My Top 10 Stocks to Buy for 2025
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too.
Negative
The Motley Fool
1 week ago
Why Viking Therapeutics Tumbled by More Than 10% This Week
News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period as a result.
Negative
Seeking Alpha
1 week ago
Viking Therapeutics: Competition Fears Are Exaggerated
Viking Therapeutics' VK2735 reported promising results in February, with significant weight loss, however, shares have returned to prices before reporting VENTURE Phase II results. The company's pipeline includes VK2809 for NASH, adding value beyond VK2735's weight-loss potential. Competition concerns are overblown; Viking's dual GLP-1/GIP agonist has competitive advantages over single-mechanism therapeutics, and concern regarding small-molecule candidates is as yet unfounded.
Positive
Seeking Alpha
1 week ago
Viking Therapeutics: Holiday Gift
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment.
Charts implemented using Lightweight Charts™